Switzerland showcases collaborative life science ecosystem at Nordic Life Science Days 2025

At Nordic Life Science Days 2025, Switzerland used a dedicated session to explain what makes its biotech and pharma environment attractive—pointing to close public-private collaboration, dense research networks, and a regulatory culture described as pragmatic and accessible. The discussion was moderated by Gustav Henriksson (Swiss Business Hub Nordics) and featured Nicolas Panzer (Switzerland Global Enterprise) and Frédéric Reymond (Innovaud).

Speakers emphasized the mix of global leaders and a large base of smaller specialist players, alongside strong talent pipelines from institutions such as ETH and EPFL and practice-oriented universities of applied sciences. They also highlighted regional strengths, including the Lake Geneva area’s high concentration of life science companies and Lausanne’s growing oncology focus supported by translational research capabilities.

Beyond talent and infrastructure, the session touched on “soft-landing” options and innovation parks that help companies plug into local networks quickly. It also addressed funding realities—venture capital is often sourced internationally (with 80% said to come from abroad)—positioning Switzerland less as a fundraising destination and more as a platform to build, test, and scale with European collaboration in mind.

Read the full article on the original source (Discover Pharma).